Minami et al [1] highlighted the relative high rate of local tumor progression (LTP) after radiofrequency ablation (RFA) for unresectable colorectal liver metastases (CRLM), ranging from 8.8 to 40%. Furthermore, the phase II CLOCC trial (NCT00043004) results demonstrated a significant improvement in disease-free survival (DFS) and overall survival (OS) in case of a combined approach compared with chemotherapy alone [2] . Thus, low LTP rate is desirable since it ultimately impacts on OS; an effective and complete local therapy with subsequent low LTP rate is the primary and prominent goal for interventional radiologists. For this purpose, both technical skills (improved by technological advancements such as ablation confirmation software development) and oncological expertise are required. Indeed, LTP rates are affected by adequate ablation margins (required margins of at least 5 mm in CRC metastases [3] ) and patients' selection considering tumor biological characteristics [4] .
the other hand, as it has been underlined in the review article by Minami et al [1] , several studies revealed that the ablation therapy positively stimulates the innate and adaptive immune system locally and globally. The understanding of interaction between the tumor debris left by the ablation and the immune system and the possible presence of minimal residual disease is a key point for further investigation in interventional oncological procedures.
The systemic scenario
In a systemic scenario, in the last two decades, target therapies have revolutionized cancer management [6] . Furthermore, in recent years, immunotherapy represented the major breakthrough in clinical cancer care with significant improvement in OS in many advanced-stage cancers (lung, melanoma, bladder, renal cell carcinoma, etc.). With the term immunotherapy, we include a wide range of treatments: cytokines, immune checkpoint inhibitors (ICIs), cancer vaccines, and cell-based immunotherapy (infusion of ex vivo-activated tumor-specific T cells). ICIs are both target therapies and a type of immunotherapy; they act by stopping the tumor immune suppression and can be considered today the most used and effective immunotherapeutic agents in clinical practice. Indeed, PD1, PD-L1, and anti CTLA4 inhibitors showed promising clinical outcomes and have been approved for many cancer treatments [7] .
The Bglocal^approach
In the future, one of the major challenges for interventional radiologists will be obtaining a comprehensive knowledge regarding the potential synergistic effect between interventional local treatments and systemic, global treatments and translating it into clinical practice.
This comment refers to the article available at https://doi.org/10.1007/ s00330-019-06189-6.
The term Bglocal^is a linguistic blend of two words, global and local, and it has had a large spread in social and economic spheres in recent years. It means, by definition, to reflect or to be characterized by both local and global considerations and analyze the bi-directional influences between local and global systems [8] .
Similarly, in a clinical oncological scenario, the term Bglocal^can be used to define the research field concerning interactions between local and systemic therapies. As well as in economical sciences, interactions between local interventions and systemic oncological treatments can be bidirectional and beneficial for both fields.
Seminal studies (recently summarized in a white paper from the Society of Interventional Oncology [9] ) have already demonstrated that this bi-directional interaction exists and should be better investigated by larger preclinical and clinical studies. Indeed, local interventions may boost the efficacy of systemic therapies by increasing the activation of tumorspecific T cells in combination with anti-CTLA4 therapies; vice versa, systemic therapies will be a useful aid to local therapies in case of persistence of minimal residual disease after ablation.
Future developments
Future researches will require to focus on the beneficial treatments for patients such as particular interventions or combined treatments and also to discover the correct timing of sequential treatments.
In the near future, three major research fields can be outlined:
1. BFrom bench to bedside^research on immune tumor micro-environment: several data are already present in the literature; however, it requires more effort by the interventional community to better understand the molecular mechanisms behind residual disease and immune system stimulation of ablation treatments; 2. The detection of minimal residual disease: the development of biomarkers to early predict recurrence before conventional cross-sectional imaging will pave the way to a correct selection of patients in case of combined treatments with systemic therapies. Development of liquid biopsy tools (early detection of circulating tumor materials with sensitive technologies) and radiomics analysis of tumors and ablation area will be of great value in this regard; 3. Timing of sequential treatments: after comprehension of the molecular mechanisms and selection of the correct patients through sensitive technologies, trials should be designed to validate the best Bglocal^approach for the right patient.
In conclusion, today more than ever, the linguistic expression Bthink globally, act locally^(often been used within the context of Bglocalization^) perfectly suits the urgent actions that interventional radiologists should take in order to integrate the local interventions within the systemic clinical scenario.
Interventional radiologists are asked to act in this multidisciplinary setting (together with medical oncologists, radiation oncologists, and surgical oncologists) as interventional oncologists, with a strong clinical background and patient-oriented mentality. This is the only way in which interventional oncology will truly grow up and will be fully recognized as the fourth pillar of oncology.
